Apollo Hospitals Q2 results: Net profit soars 26% YoY to ₹477 crore, revenue advances 13%

In the year-ago period, it had clocked a profit of ₹378.8 crore, it said in a regulatory filing.

The country's largest private hospital chain operator witnessed a 12.8% YoY surge in its revenue from operations to ₹6,304 crore during the quarter under review, compared to ₹5,589 crore in the September quarter of the 2024-25 fiscal year (Q2FY25).

During the quarter, its revenue from the healthcare services (or hospitals) segment advanced by 9% YoY to ₹3,169 crore, from ₹2,903 crore in the corresponding period of the previous fiscal year, with a reduction in Bangladesh patients impacting 1% on this segment’s revenue.

Its gross revenue from Apollo Health and Lifestyle Limited (Diagnostics and Retail Healthcare) stood at ₹474 crore, reflecting a 17% YoY increase, with diagnostics revenue at ₹183 crore and Spectra at ₹73 crore.

The hospital chain’s overall Health Co business rose 17% YoY to ₹2,661 crore, it said.

At an operational level, its EBITDA (earnings before interest, tax, depreciation, and amortisation), also known as operating profit, stood at ₹941 crore in the September quarter of the current fiscal year, marking a 15.3% annual increase from ₹816 crore in the same quarter of FY25.

Its EBITDA margin expanded by a little over two basis points (bps) YoY to 14.94% in Q2FY26, as against 14.59% in the year-ago period.

Commenting on the earnings, Dr. Prathap C Reddy, Chairman, Apollo Hospitals Enterprise Ltd., said: “During the quarter, the Competition Commission of India approved the restructuring plan involving our group entities, Apollo Healthco, Keimed, and Apollo Healthtech, allowing us to move further on the reorganisation exercise to unlock value for our shareholders.”

He said that on the operational side, the hospitals continued to attract complex cases from India and beyond, achieving a 69% occupancy and a 9% increase in revenue, adding, “Our focus on quality, efficiency, and superior patient outcomes has enabled us to maintain steady margins while delivering on our promise of world-class care at affordable costs.”

“In the coming quarters, we will continue to deepen our technology partnerships, expand our AI capabilities and drive sustainable improvements through quality-led differentiation. With robust capacity addition in progress and ongoing clinical innovations in areas such as precision oncology and robotic surgery, we are more confident than ever in our ability to deliver superior care while creating long-term value for all our stakeholders,” he said.

Apollo Hospitals Enterprise's total market capitalisation stood at ₹1.12 lakh crore, as of November 6, 2025, according to data on the NSE.